KR102038948B1 - 알파 코넥신 c-말단 (act) 펩타이드를 포함하는 국소 겔 - Google Patents

알파 코넥신 c-말단 (act) 펩타이드를 포함하는 국소 겔 Download PDF

Info

Publication number
KR102038948B1
KR102038948B1 KR1020147027397A KR20147027397A KR102038948B1 KR 102038948 B1 KR102038948 B1 KR 102038948B1 KR 1020147027397 A KR1020147027397 A KR 1020147027397A KR 20147027397 A KR20147027397 A KR 20147027397A KR 102038948 B1 KR102038948 B1 KR 102038948B1
Authority
KR
South Korea
Prior art keywords
arg
ser
lys
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147027397A
Other languages
English (en)
Korean (ko)
Other versions
KR20140132388A (ko
Inventor
가우탐 가트너카르
Original Assignee
퍼스트스트링 리서치 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 퍼스트스트링 리서치 인코포레이티드 filed Critical 퍼스트스트링 리서치 인코포레이티드
Publication of KR20140132388A publication Critical patent/KR20140132388A/ko
Application granted granted Critical
Publication of KR102038948B1 publication Critical patent/KR102038948B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
KR1020147027397A 2012-03-01 2013-03-01 알파 코넥신 c-말단 (act) 펩타이드를 포함하는 국소 겔 Active KR102038948B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605528P 2012-03-01 2012-03-01
US61/605,528 2012-03-01
PCT/US2013/028727 WO2013131040A1 (en) 2012-03-01 2013-03-01 Topical gels containing alpha connexin c-terminal (act) peptides

Publications (2)

Publication Number Publication Date
KR20140132388A KR20140132388A (ko) 2014-11-17
KR102038948B1 true KR102038948B1 (ko) 2019-11-26

Family

ID=49083360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147027397A Active KR102038948B1 (ko) 2012-03-01 2013-03-01 알파 코넥신 c-말단 (act) 펩타이드를 포함하는 국소 겔

Country Status (17)

Country Link
US (5) US8846605B2 (enExample)
EP (1) EP2819682B1 (enExample)
JP (1) JP6185937B2 (enExample)
KR (1) KR102038948B1 (enExample)
CN (1) CN104271142B (enExample)
AU (1) AU2013225716B2 (enExample)
BR (1) BR112014021653B1 (enExample)
CA (1) CA2866115C (enExample)
DK (1) DK2819682T3 (enExample)
IL (1) IL234380B (enExample)
IN (1) IN2014DN07420A (enExample)
MX (1) MX351881B (enExample)
NZ (1) NZ629769A (enExample)
RU (1) RU2657535C2 (enExample)
SG (1) SG11201405359YA (enExample)
WO (1) WO2013131040A1 (enExample)
ZA (1) ZA201406373B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
JP6185937B2 (ja) 2012-03-01 2017-08-23 ファーストストリング・リサーチ・インコーポレイテッドFirststring Research,Inc. アルファコネキシンc末端(act)ペプチド含有局所用ゲル剤
US11246821B2 (en) * 2016-08-30 2022-02-15 Rohm And Haas Company Personal care composition
MX2019009753A (es) * 2017-02-16 2019-12-18 Firststring Res Inc Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
US20210137809A1 (en) * 2017-06-14 2021-05-13 Biosolution Co., Ltd Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN112969451A (zh) * 2018-09-12 2021-06-15 福斯特斯特林研究公司 使用α连接蛋白C端肽的纳米粒子制剂和方法
RU2691647C1 (ru) * 2018-11-29 2019-06-17 Артем Иванович Трофименко Средство для профилактики образования патологических кожных рубцов
US11751056B2 (en) * 2020-08-31 2023-09-05 Oracle International Corporation Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns
CN116710474A (zh) 2020-10-22 2023-09-05 撒凯尔生物公司 肽制剂及其眼科用途
WO2023212446A1 (en) * 2022-04-29 2023-11-02 Xequel Bio, Inc. Compositions and methods for treating complications of viral infections and other respiratory disorders
CN117582401B (zh) * 2023-12-07 2024-04-26 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065770A1 (en) 1999-01-27 2011-03-17 David Laurence Becker Formulations comprising antisense nucleotides to connexins

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603444A1 (de) 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
CA2080538A1 (en) 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5401504B1 (en) * 1993-12-28 1998-04-21 Univ Mississippi Medical Cente Use of tumeric in wound healing
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
WO2000069896A2 (en) 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in haematopoietic cells
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
AU2002239336A1 (en) 2000-11-10 2002-06-03 Arbor Vita Corporation Molecular interactions in hematopoietic cells
WO2002088370A2 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Autogene nucleic acids encoding a secretable rna polymerase
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
US6685971B2 (en) 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
CA2457424A1 (en) 2001-08-03 2003-02-20 Arbor Vita Corporation Molecular interactions in cells
WO2003032964A2 (en) 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
US20030215424A1 (en) 2002-05-15 2003-11-20 Seul Kyung Hwan Method of modulating angiogenesis
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
US7560430B2 (en) 2003-02-14 2009-07-14 Human Matrix Sciences, Llc Elastin digest compositions and methods utilizing same
US8034789B2 (en) 2003-12-03 2011-10-11 Coda Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
EP1827480B1 (en) 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
CN101151043B (zh) * 2004-12-21 2013-09-04 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
AU2006257283A1 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
US20090131313A1 (en) * 2005-06-17 2009-05-21 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods for treating or preventing tissue deterioration, injury or damage
CN101198346A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 Lkktet和/或lkktnt肽组合物及方法
EP1945307B1 (en) * 2005-10-11 2013-03-27 DPT Laboratories, LTD. Surfactant-free dispersions, compositions, and use in topical formulations
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
CA2672220A1 (en) 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
JP5552048B2 (ja) 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント 加齢性黄斑変性を治療するためのアルファコネキシンc末端(act)ペプチド
CA2592285C (en) 2007-06-28 2019-10-01 Musc Foundation For Research Development Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides
CA2709151A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2009075882A2 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CA2710388A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars
US20110245184A1 (en) 2007-12-21 2011-10-06 Bradford James Duft Treatment of surgical adhesions
CA2710232A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
WO2009085271A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
WO2009085272A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
JP2011507857A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス, インコーポレイテッド 線維症性の状態の処置のためのコネキシン43の阻害剤の使用
CA2710227A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of surgical adhesions
WO2009085275A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
AU2008343840A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
CA2711635A1 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments
CA2727015A1 (en) 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
JP6185937B2 (ja) 2012-03-01 2017-08-23 ファーストストリング・リサーチ・インコーポレイテッドFirststring Research,Inc. アルファコネキシンc末端(act)ペプチド含有局所用ゲル剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065770A1 (en) 1999-01-27 2011-03-17 David Laurence Becker Formulations comprising antisense nucleotides to connexins

Also Published As

Publication number Publication date
CN104271142B (zh) 2017-07-04
CA2866115C (en) 2020-03-24
HK1205451A1 (en) 2015-12-18
EP2819682A4 (en) 2016-01-06
NZ629769A (en) 2016-09-30
US8846605B2 (en) 2014-09-30
SG11201405359YA (en) 2014-09-26
US10632173B2 (en) 2020-04-28
KR20140132388A (ko) 2014-11-17
MX351881B (es) 2017-11-01
DK2819682T3 (en) 2017-08-21
US20230263857A1 (en) 2023-08-24
EP2819682B1 (en) 2017-05-03
US12128086B2 (en) 2024-10-29
JP2015513549A (ja) 2015-05-14
US20210128682A1 (en) 2021-05-06
US20130267471A1 (en) 2013-10-10
RU2657535C2 (ru) 2018-06-14
CA2866115A1 (en) 2013-09-06
RU2014139668A (ru) 2016-04-20
EP2819682A1 (en) 2015-01-07
IN2014DN07420A (enExample) 2015-04-24
AU2013225716A1 (en) 2014-09-18
US11524049B2 (en) 2022-12-13
US20160058834A1 (en) 2016-03-03
US20150018284A1 (en) 2015-01-15
WO2013131040A1 (en) 2013-09-06
MX2014010501A (es) 2015-03-09
JP6185937B2 (ja) 2017-08-23
CN104271142A (zh) 2015-01-07
BR112014021653A2 (pt) 2022-05-10
AU2013225716B2 (en) 2017-10-12
BR112014021653B1 (pt) 2023-03-28
ZA201406373B (en) 2015-12-23
US9161984B2 (en) 2015-10-20
IL234380B (en) 2020-10-29

Similar Documents

Publication Publication Date Title
KR102038948B1 (ko) 알파 코넥신 c-말단 (act) 펩타이드를 포함하는 국소 겔
TWI593421B (zh) 凍乾的重組vwf調配物
ES2236010T3 (es) Composiciones de polipeptidos con estabilidad mejorada.
KR101752508B1 (ko) 제8 인자 제형
JP3723857B2 (ja) ヒト成長ホルモン含有水性医薬組成物
AU2006268091B2 (en) Promotion of epithelial regeneration
JP2003504346A (ja) 成長ホルモン製剤
JP2023166014A (ja) コラーゲン7組成物及びそれを用いる方法
CA3011609A1 (en) A lyophilised pharmaceutical formulation and its use
JP2010536906A (ja) G−csfの液体製剤
US20230052378A1 (en) Peptide-containing composition for use for treating neoplastic lesions
HK1205451B (en) Topical gels containing alpha connexin c-terminal (act) peptides

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140929

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190403

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190801

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191025

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191028

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221013

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20231012

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20241017

Start annual number: 6

End annual number: 6